Skip to content

Serotonin research published in 2016

Page 2 of 3: studies 21 to 40 of 46, newest first. Back to the serotonin overview

Studies

Neurotoxic Effects of 5-MeO-DIPT: A Psychoactive Tryptamine Derivative in Rats

Neurotoxicity Research July 26, 2016 Karolina Noworyta, Katarzyna Kamińska, Grzegorz Kreiner et al. 26 citations

5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT, 'foxy') is one of the most popular tryptamine hallucinogens in the illicit drug market. It produces serious adverse effects, but its pharmacological profile is not well recognized. In vitro data have shown that 5-MeO-DIPT acts as a potent serotonin transporter (SERT) inhibitor and displays high affinity at serotonin 5-HT1A, 5-HT2A, and 5-HT2C...

ChemInform Abstract: Observations Concerning the Synthesis of Tryptamine Homologues and Branched Tryptamine Derivatives via the Borrowing Hydrogen Process: Synthesis of Psilocin, Bufotenin, and Serotonin.

ChemInform July 1, 2016 Silvia Bartolucci, Michele Mari, Giovanni Di Gregorio et al.

AbstractThe selective indole alkylation reaction applying the Ir‐catalyzed‐borrowing hydrogen methodology and using amino alcohols (II), (V), (VII) as suitable nitrogen‐containing electrophiles is reported.

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor

Journal of Psychosocial Nursing and Mental Health Services June 30, 2016 Robert H Howland 22 citations

Antidepressant, atypical antipsychotic, and hallucinogen drugs mediate their actions in part by interactions with the serotonin-2A (5HT2A) receptor. Serotonergic hallucinogen drugs, such as psilocybin, bind most potently as agonists at the 5HT2A receptor, producing profound changes in perception, mood, and cognition. Some of these drugs have been or are currently being investigated in small...

Pharmacological Investigations of the Dissociative ‘Legal Highs’ Diphenidine, Methoxphenidine and Analogues

PLoS One June 17, 2016 Jason Wallach, Heather Kang, Tristan Colestock et al. 73 citations

1,2-Diarylethylamines including lanicemine, lefetamine, and remacemide have clinical relevance in a range of therapeutic areas including pain management, epilepsy, neurodegenerative disease and depression. More recently 1,2-diarylethylamines have been sold as 'legal highs' in a number of different forms including powders and tablets. These compounds are sold to circumvent governmental...

DOI: 10.1371/journal.pone.0157021 (opens in new tab) Serotonin Pharmacology Dopamine Norepinephrine transporter +5

Ligand induced conformational changes of the human serotonin transporter revealed by molecular dynamics simulations.

PLoS One June 14, 2016 Heidi Koldsø, Henriette Elisabeth Autzen, Julie Grouleff et al.

The competitive inhibitor cocaine and the non-competitive inhibitor ibogaine induce different conformational states of the human serotonin transporter. It has been shown from accessibility experiments that cocaine mainly induces an outward-facing conformation, while the non-competitive inhibitor ibogaine, and its active metabolite noribogaine, have been proposed to induce an inward-facing...

Modification of 5-methoxy-N,N-dimethyltryptamine-induced hyperactivity by monoamine oxidase A inhibitor harmaline in mice and the underlying serotonergic mechanisms.

Pharmacological Reports June 1, 2016 Xi-Ling Jiang, Hong-Wu Shen, Ai-Ming Yu 13 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and harmaline are indolealkylamine (IAA) drugs often abused together. Our recent studies have revealed the significant effects of co-administered harmaline, a monoamine oxidase inhibitor (MAOI), on 5-MeO-DMT pharmacokinetics and thermoregulation. This study was to delineate the impact of harmaline and 5-MeO-DMT on home-cage activity in mouse models,...

DOI: 10.1016/j.pharep.2016.01.008 (opens in new tab) Full text (opens in new tab) 5-HT Receptor Harmaline Maoi 5-MEO-DMT Combination +14

Control of serotonin transporter phosphorylation by conformational state.

Proceedings of the National Academy of Sciences May 17, 2016 Yuan-Wei Zhang, Benjamin E Turk, Gary Rudnick 53 citations

Serotonin transporter (SERT) is responsible for reuptake and recycling of 5-hydroxytryptamine (5-HT; serotonin) after its exocytotic release during neurotransmission. Mutations in human SERT are associated with psychiatric disorders and autism. Some of these mutations affect the regulation of SERT activity by cGMP-dependent phosphorylation. Here we provide direct evidence that this...

DOI: 10.1073/pnas.1603282113 (opens in new tab) Full text (opens in new tab) Ibogaine Phosphorylation Serotonin transporter Conformational regulation

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing

Proceedings of the National Academy of Sciences April 18, 2016 Katrin H. Preller, Thomas Pokorny, Andreas Hock et al. 175 citations

Social ties are crucial for physical and mental health. However, psychiatric patients frequently encounter social rejection. Moreover, an increased reactivity to social exclusion influences the development, progression, and treatment of various psychiatric disorders. Nevertheless, the neuromodulatory substrates of rejection experiences are largely unknown. The preferential serotonin (5-HT)...

Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.

Neuropharmacology April 1, 2016 R. Linge, Laura Jiménez-Sánchez, L. Campa et al.

Cannabidiol (CBD), the main non-psychotomimetic component of marihuana, exhibits anxiolytic-like properties in many behavioural tests, although its potential for treating major depression has been poorly explored. Moreover, the mechanism of action of CBD remains unclear. Herein, we have evaluated the effects of CBD following acute and chronic administration in the olfactory bulbectomy mouse...

MDMA self-administration fails to alter the behavioral response to 5-HT(1A) and 5-HT(1B) agonists.

Psychopharmacology April 2016 Dane Aronsen, Susan Schenk

Regular use of the street drug, ecstasy, produces a number of cognitive and behavioral deficits. One possible mechanism for these deficits is functional changes in serotonin (5-HT) receptors as a consequence of prolonged 3,4 methylenedioxymethamphetamine (MDMA)-produced 5-HT release. Of particular interest are the 5-HT(1A) and 5-HT(1B) receptor subtypes since they have been implicated in...

Repeated administration of the 5-HT₁B/₁A agonist, RU 24969, facilitates the acquisition of MDMA self-administration: role of 5-HT₁A and 5-HT₁B receptor mechanisms.

Psychopharmacology April 2016 Dane Aronsen, Natasha Bukholt, Susan Schenk

3,4 Methylenedioxymethamphetamine (MDMA) preferentially stimulates the release of serotonin (5-HT) that subsequently produces behavioral responses by activation of post-synaptic receptor mechanisms. The 5-HT1A and 5-HT1B receptors are both well localized to regulate dopamine (DA) release, and have been implicated in modulating the reinforcing effects of many drugs of abuse, but a role in...

Meta-analysis of molecular imaging of serotonin transporters in ecstasy/polydrug users.

Neuroscience & Biobehavioral Reviews April 2016 Carl Alexander Roberts, Andrew Jones, Catharine Montgomery

We conducted a meta-analysis on the available data from studies investigating SERTs in ecstasy users and polydrug using controls. From 7 studies we compared data from 157 ecstasy users and 148 controls across 14 brain regions. The main effect suggested ecstasy/MDMA related SERT reductions (SMD=0.52, 95% CIs [0.40, 0.65]; Z=8.36, p<.01, I(2)=89%). A significant effect of subgroups (X(2)=37.41,...

Effect of Some Psychoactive Drugs Used as ‘Legal Highs’ on Brain Neurotransmitters

Neurotoxicity Research April 1, 2016 Krystyna Gołembiowska, Alexandra Jurczak, Katarzyna Kamińska et al.

New psychoactive “designer drugs” are synthetic compounds developed to provide similar effects to illicit drugs of abuse, but not subjected to legal control. The rapidly changing legal status of novel psychoactive drugs triggers the development of new compounds, analogs of well-known amphetamine or mescaline. New designer drugs used as substitutes in ecstasy pills are the least investigated and...

Lysergic Acid Diethylamide (LSD) Modulates Circadian Activity Behavior And The Expression Level of Circadian Genes in Drosophila melanogaster in Both Sexes

The FASEB Journal April 1, 2016 Kelly Jean Sherman, Charles D. Nichols

Circadian rhythms modulate biochemical and molecular pathways in living systems. In humans an endogenous clock mechanism is synchronized by a daily light‐dark cycle: sun up and sun down. These external cues from the environment regulate the core‐clock through auto‐regulating circadian genes’ expression levels. These oscillating gene products modulate physiological, biochemical, and molecular...

DOI: 10.1096/fasebj.30.1_supplement.930.4 (opens in new tab) Serotonin Circadian rhythm Circadian clock Drosophila melanogaster +5

Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans

European Neuropsychopharmacology March 26, 2016 Marta Valle, Ana Maqueda, Mireia Rabella et al. 175 citations

Ayahuasca is an Amazonian psychotropic plant tea typically obtained from two plants, Banisteriopsis caapi and Psychotria viridis. It contains the psychedelic 5-HT2A and sigma-1 agonist N,N-dimethyltryptamine (DMT) plus β-carboline alkaloids with monoamine-oxidase (MAO)-inhibiting properties. Although the psychoactive effects of ayahuasca have commonly been attributed solely to agonism at the...

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models

Zebrafish March 22, 2016 Evan J. Kyzar, Allan V. Kalueff 29 citations

After decades of sociopolitical obstacles, the field of psychiatry is experiencing a revived interest in the use of hallucinogenic agents to treat brain disorders. Along with the use of ketamine for depression, recent pilot studies have highlighted the efficacy of classic serotonergic hallucinogens, such as lysergic acid diethylamide and psilocybin, in treating addiction, post-traumatic stress...

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans

The International Journal of Neuropsychopharmacology February 12, 2016 Marta Valle, Montserrat Puntes, Jimena Coimbra et al. 31 citations

BACKGROUND: Salvinorin-A is a terpene found in the leaves of the plant Salvia divinorum. When administered to humans, salvinorin-A induces an intense but short-lasting modified state of awareness, sharing features with those induced by the classical serotonin-2A receptor agonist psychedelics. However, unlike substances such as psilocybin or mescaline, salvinorin-A shows agonist activity at the...

The serotonergic hallucinogen 5-methoxy-N,N-dimethyltryptamine disrupts cortical activity in a regionally-selective manner via 5-HT(1A) and 5-HT(2A) receptors.

Neuropharmacology February 1, 2016 Maurizio S Riga, Analia Bortolozzi, Letizia Campa et al. 33 citations

5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a natural hallucinogen, acting as a non-selective serotonin 5-HT(1A)/5-HT(2A)-R agonist. Psychotomimetic agents such as the non-competitive NMDA-R antagonist phencyclidine and serotonergic hallucinogens (DOI and 5-MeO-DMT) disrupt cortical synchrony in the low frequency range (<4 Hz) in rat prefrontal cortex (PFC), an effect reversed by...

DOI: 10.1016/j.neuropharm.2015.10.016 (opens in new tab) Full text (opens in new tab) 5-HT Receptors Oscillatory activity Prefrontal cortex Sensorial cortical areas +10

Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.

Toxicology Letters January 22, 2016 Andrea E. Steuer, Martina I. Boxler, Lorena Stock et al.

Neurotoxicity of 3,4-methylenedioxymethamphetamine (MDMA) is still controversially discussed. Formation of reactive oxygen species e.g. based on elevated dopamine (DA) concentrations and DA quinone formation is discussed among others. Inhibition potential of MDMA metabolites regarding neurotransmitter degradation by catechol-O-methyltransferase and sulfotransferase was described previously....

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience

European Neuropsychopharmacology January 22, 2016 Thomas Pokorny, Katrin H. Preller, Rainer Kraehenmann et al. 148 citations

The mixed serotonin (5-HT) 1A/2A/2B/2C/6/7 receptor agonist psilocybin dose-dependently induces an altered state of consciousness (ASC) that is characterized by changes in sensory perception, mood, thought, and the sense of self. The psychological effects of psilocybin are primarily mediated by 5-HT2A receptor activation. However, accumulating evidence suggests that 5-HT1A or an interaction...

DOI: 10.1016/j.euroneuro.2016.01.005 (opens in new tab) Psilocybin Buspirone Hallucinogen 5-ht1 receptor +5